The offer price of the voluntary conditional cash offer is HK$1.25 per share in cash, representing a premium of approximately 12.61% over the closing price of HK$1.11 per share on 12 January 2017 (the "Last Trading Day") and a premium of approximately 20.19% over the average closing price of HK$1.04 per share for the last 30 trading days prior to and including the Last Trading Day.
The funds required by the voluntary conditional cash offer will be financed from MO3's internal resources as well as the issuance of notes by MO3 to China Minsheng Banking Corp., Ltd. Amasse Capital Limited is acting as the financial adviser to MO3.
Further details of the voluntary conditional cash offer have been published by the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and posted on the Company's website as follows: http://www.goldenmeditech.com/eng/ir/announcements.php
About Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801)
Golden Meditech (www.goldenmeditech.com) is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market, the cord blood storage market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/golden-meditechs-controlling-shareholder-proposed-a-voluntary-conditional-cash-offer-at-hk125-per-share-300390777.html
SOURCE Golden Meditech Holdings Limited